Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Repare Therapeutics Inc. (RPTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 8-K reports that describe material events and corporate transactions. Repare’s common shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and trade on The Nasdaq Stock Market LLC under the symbol RPTX, as reflected in its filings. These documents offer insight into the company’s precision oncology business, strategic agreements, and planned change in corporate structure.
Recent Form 8-K filings detail key developments such as the arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp., under which Xeno will acquire all issued and outstanding common shares of Repare through a court-approved plan of arrangement under the Business Corporations Act (Québec). The November 17, 2025 8-K describes the transaction terms, including a cash amount per share based on closing net cash and the issuance of non-transferable contingent value rights (CVRs) that entitle holders to potential future cash payments tied to specified receivables, partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, and licensing or disposition of product candidates and intellectual property.
Other 8-K filings referenced in 2025 address topics such as quarterly financial results, executive compensation and severance arrangements, and scientific and clinical communications, including the availability of abstracts related to the Phase 1 LIONS trial of RP-1664. These filings complement Repare’s press releases by providing formal regulatory descriptions of material agreements, voting and support arrangements with directors and officers, and conditions to closing for the Xeno transaction.
On Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain complex sections, highlight the practical implications of items such as CVR structures, termination fees or voting thresholds, and help interpret how agreements and disclosures relate to Repare’s precision oncology programs. The page also serves as a reference point for tracking Repare’s transition from a Nasdaq-listed issuer toward becoming a privately held company, as described in its public filings and transaction announcements.
Repare Therapeutics Inc. (Nasdaq: RPTX) filed a Form 8-K to disclose changes approved by its Compensation Committee on June 13, 2025 to the severance package of Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer.
Under the amended terms, if Dr. Zinda is terminated without “cause” or resigns for “good reason,” and the separation is not in connection with a change-in-control, he will receive:
- Lump-sum cash equal to nine months of current base salary.
- COBRA premiums paid by Repare for up to 12 months post-separation.
- Accelerated vesting of all unvested equity awards for nine months from the separation date.
- Pro-rated target bonus for the year of separation, paid in a lump sum.
If a change in control occurs within 90 days after the separation date, Dr. Zinda will instead receive the enhanced change-in-control severance stipulated in Section 5.7(c) of his previously disclosed Employment Agreement. All other existing severance protections in that agreement remain unchanged.
The disclosure is limited to executive compensation; no financial results, operational updates, or strategic transactions were reported.